尾-cyclodextrin–eslicarbazepine acetate complex developed with enhanced solubility.
Formulated Orally disintegrating tablets (ODT) disintegrated within 30 s.
Bioavailability from ODT was 2 times higher than marketed tablets.
Onset of action for ODT was also faster than marketed tablets.
Formulated ODT would aid epileptic patients incapable of swallowing tablets.